A Randomized, Double-Blind, Parallel-Design, Placebo-Controlled Study to Evluate the Efficacy and Safety of Tadalafil (2.5 mg e 5 mg) administered once daily to men with diabetes mellitus and erectile dysfunctio

Active, not recruiting

• Conditions: Therapy of erectile disfunction to subjects with diabetes mellitus and erectile disfunction with a 2.5 mg or 5 mg daily dosing.; MedDRA version: 6.1Level: PTClassification code 10061461

• Registration Number: EUCTR2004-001033-41-IT
• Lead Sponsor: ELI LILLY

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2004-09-14
• Last Update Posted: 19 March 2012

Recruitment & Eligibility

• Status: Not Recruiting
• Sex: Male
• Target Recruitment: Not specified

Inclusion Criteria

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range

Exclusion Criteria

Not provided

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Main Objective: ;Secondary Objective: ;Primary end point(s):